ES2753777T3 - Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas - Google Patents
Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas Download PDFInfo
- Publication number
- ES2753777T3 ES2753777T3 ES16720421T ES16720421T ES2753777T3 ES 2753777 T3 ES2753777 T3 ES 2753777T3 ES 16720421 T ES16720421 T ES 16720421T ES 16720421 T ES16720421 T ES 16720421T ES 2753777 T3 ES2753777 T3 ES 2753777T3
- Authority
- ES
- Spain
- Prior art keywords
- purin
- methyl
- amino
- compound
- propylsulfonimidoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O Chemical compound *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O 0.000 description 17
- DYZHAGOFOBOPJC-MHBAEANFSA-N C/C=C\C=C(/CC#C)\C[N](C)(c1nc(S(C)(=NC=O)=O)nc(N)c1N1)C1=O Chemical compound C/C=C\C=C(/CC#C)\C[N](C)(c1nc(S(C)(=NC=O)=O)nc(N)c1N1)C1=O DYZHAGOFOBOPJC-MHBAEANFSA-N 0.000 description 1
- DIEPCGMINUKNDB-UHFFFAOYSA-N CCCC(CCC)C(N(C)c(nc(nc1N2Cc3ccccc3)S(CCC)(=N)=O)c1NC2=O)=O Chemical compound CCCC(CCC)C(N(C)c(nc(nc1N2Cc3ccccc3)S(CCC)(=N)=O)c1NC2=O)=O DIEPCGMINUKNDB-UHFFFAOYSA-N 0.000 description 1
- KOWJQKOPIUCLLW-UHFFFAOYSA-N CCCS(c(nc1N)nc(N2Cc3ccc(C)nc3)c1NC2=O)=O Chemical compound CCCS(c(nc1N)nc(N2Cc3ccc(C)nc3)c1NC2=O)=O KOWJQKOPIUCLLW-UHFFFAOYSA-N 0.000 description 1
- VZUZSTAHFWXVQJ-UHFFFAOYSA-N CCCS(c(nc1N2CC(C)C)nc(N)c1NC2O)(=N)=O Chemical compound CCCS(c(nc1N2CC(C)C)nc(N)c1NC2O)(=N)=O VZUZSTAHFWXVQJ-UHFFFAOYSA-N 0.000 description 1
- YJXYKDUWIFDOMI-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(CC(C)C)=O)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(CC(C)C)=O)c1NC2=O)(=N)=O YJXYKDUWIFDOMI-UHFFFAOYSA-N 0.000 description 1
- XMHYHSKQEHLLOK-UHFFFAOYSA-N CCCSc(nc1Cl)nc(NCc(cc2)ccc2C(OC)=O)c1N Chemical compound CCCSc(nc1Cl)nc(NCc(cc2)ccc2C(OC)=O)c1N XMHYHSKQEHLLOK-UHFFFAOYSA-N 0.000 description 1
- AWMRXUUYVORZPB-UHFFFAOYSA-N CCCSc(nc1N)nc(N2Cc(cc3)cc(F)c3F)c1NC2=O Chemical compound CCCSc(nc1N)nc(N2Cc(cc3)cc(F)c3F)c1NC2=O AWMRXUUYVORZPB-UHFFFAOYSA-N 0.000 description 1
- BCCIMILKWSTHDD-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(Cl)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(Cl)c1NC2=O BCCIMILKWSTHDD-UHFFFAOYSA-N 0.000 description 1
- JJGRPZNRJBBDDL-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc([I]=[IH])ccc3)nc(Cl)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc([I]=[IH])ccc3)nc(Cl)c1NC2=O JJGRPZNRJBBDDL-UHFFFAOYSA-N 0.000 description 1
- BRSQFEYCEJEYCJ-UHFFFAOYSA-N CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O Chemical compound CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O BRSQFEYCEJEYCJ-UHFFFAOYSA-N 0.000 description 1
- WBQWVGJKURKLHU-UHFFFAOYSA-N COc1ccc(CN(C(N)=C(C#N)N2)C2=O)cc1 Chemical compound COc1ccc(CN(C(N)=C(C#N)N2)C2=O)cc1 WBQWVGJKURKLHU-UHFFFAOYSA-N 0.000 description 1
- GJZIAFLOUZRSMO-UHFFFAOYSA-N CS(c(nc1N2Cc3cccnc3)nc(N)c1NC2=O)=O Chemical compound CS(c(nc1N2Cc3cccnc3)nc(N)c1NC2=O)=O GJZIAFLOUZRSMO-UHFFFAOYSA-N 0.000 description 1
- WNRUNFGVYGGGEW-UHFFFAOYSA-N CSc(nc1NCc2cc[n]cc2)nc(Cl)c1N Chemical compound CSc(nc1NCc2cc[n]cc2)nc(Cl)c1N WNRUNFGVYGGGEW-UHFFFAOYSA-N 0.000 description 1
- QXUVSSHJGKGJNJ-UHFFFAOYSA-N CSc(nc1NCc2cccnc2)nc(Cl)c1N Chemical compound CSc(nc1NCc2cccnc2)nc(Cl)c1N QXUVSSHJGKGJNJ-UHFFFAOYSA-N 0.000 description 1
- FGGHMITXKSUZKF-UHFFFAOYSA-N Nc(nc(nc1N2Cc3ccccc3)SCC3CCCCC3)c1NC2=O Chemical compound Nc(nc(nc1N2Cc3ccccc3)SCC3CCCCC3)c1NC2=O FGGHMITXKSUZKF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 | ||
| PCT/EP2016/059961 WO2016180695A1 (en) | 2015-05-08 | 2016-05-04 | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2753777T3 true ES2753777T3 (es) | 2020-04-14 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16720421T Active ES2753777T3 (es) | 2015-05-08 | 2016-05-04 | Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (OSRAM) |
| EP (1) | EP3294740B1 (OSRAM) |
| JP (1) | JP6738352B2 (OSRAM) |
| KR (1) | KR102690131B1 (OSRAM) |
| CN (1) | CN107580596B (OSRAM) |
| AR (1) | AR104528A1 (OSRAM) |
| AU (3) | AU2016260683B2 (OSRAM) |
| BR (1) | BR112017023959B1 (OSRAM) |
| CA (1) | CA2982704C (OSRAM) |
| CL (1) | CL2017002745A1 (OSRAM) |
| CO (1) | CO2017009994A2 (OSRAM) |
| CR (1) | CR20170496A (OSRAM) |
| DK (1) | DK3294740T3 (OSRAM) |
| ES (1) | ES2753777T3 (OSRAM) |
| HR (1) | HRP20191942T1 (OSRAM) |
| HU (1) | HUE045906T2 (OSRAM) |
| IL (2) | IL254947B (OSRAM) |
| LT (1) | LT3294740T (OSRAM) |
| MX (2) | MX393198B (OSRAM) |
| MY (1) | MY182353A (OSRAM) |
| NZ (2) | NZ775222A (OSRAM) |
| PE (1) | PE20171620A1 (OSRAM) |
| PH (1) | PH12017502009A1 (OSRAM) |
| PL (1) | PL3294740T3 (OSRAM) |
| PT (1) | PT3294740T (OSRAM) |
| RS (1) | RS59435B1 (OSRAM) |
| RU (1) | RU2745269C2 (OSRAM) |
| SG (1) | SG10202108841YA (OSRAM) |
| SI (1) | SI3294740T1 (OSRAM) |
| TW (2) | TWI706954B (OSRAM) |
| UA (1) | UA120450C2 (OSRAM) |
| WO (1) | WO2016180695A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ775222A (en) * | 2015-05-08 | 2024-09-27 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| IL284255B (en) | 2016-08-29 | 2022-07-01 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| TWI720250B (zh) * | 2016-09-13 | 2021-03-01 | 瑞士商赫孚孟拉羅股份公司 | 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療 |
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| JP7089596B2 (ja) * | 2018-02-28 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| WO2020168017A1 (en) * | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| EP4031544B1 (en) | 2019-09-20 | 2024-02-28 | Syngenta Crop Protection AG | Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents |
| WO2021154662A1 (en) * | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP7684316B2 (ja) * | 2020-01-27 | 2025-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| EP4554678A1 (en) | 2022-07-14 | 2025-05-21 | F. Hoffmann-La Roche AG | Phosphorylpurinone compounds for the treatment of cancer |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| EA200702235A1 (ru) * | 2005-05-04 | 2008-04-28 | Пфайзер Лимитед | Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| CA2745295C (en) * | 2008-12-09 | 2017-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2776439B1 (en) * | 2011-11-09 | 2018-07-04 | Janssen Sciences Ireland UC | Purine derivatives for the treatment of viral infections |
| BR112015024411B1 (pt) | 2013-03-29 | 2022-02-22 | Janssen Sciences Ireland Uc | Desaza-purinonas macrocíclicas para o tratamento de infeções virais e composição farmacêutica que os compreende |
| AU2015303558B2 (en) | 2014-08-15 | 2018-07-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| NZ775222A (en) * | 2015-05-08 | 2024-09-27 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| IL284255B (en) * | 2016-08-29 | 2022-07-01 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2016
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt active IP Right Grant
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh active
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2753777T3 (es) | Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas | |
| JP6957518B2 (ja) | 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物 | |
| JP6936848B2 (ja) | 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物 | |
| ES3026145T3 (en) | Inhibitors of human immunodeficiency virus replication | |
| US10457687B2 (en) | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| RU2540332C2 (ru) | Бициклические азотсодержащие гетероциклические соединения, полезные при лечении гепатита с | |
| KR20150092279A (ko) | 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진 | |
| KR20230074762A (ko) | 사이클린-의존성 키나제 7(cdk7) 비-공유 저해제 | |
| WO2021063852A1 (en) | Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection | |
| KR20180025928A (ko) | 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체 | |
| AU2018360478B2 (en) | BTK inhibitor compounds | |
| CN116867782A (zh) | 吡唑酰胺衍生物 | |
| HK1247925B (zh) | 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物 | |
| CN107406452B (zh) | 吡唑并[3,4-d]嘧啶衍生物及其治疗利什曼病的用途 |